DE69330137D1 - Die kombination von antineoplastischen mitteln und antisense-oligonukleotiden bei der behandlung von krebs - Google Patents

Die kombination von antineoplastischen mitteln und antisense-oligonukleotiden bei der behandlung von krebs

Info

Publication number
DE69330137D1
DE69330137D1 DE69330137T DE69330137T DE69330137D1 DE 69330137 D1 DE69330137 D1 DE 69330137D1 DE 69330137 T DE69330137 T DE 69330137T DE 69330137 T DE69330137 T DE 69330137T DE 69330137 D1 DE69330137 D1 DE 69330137D1
Authority
DE
Germany
Prior art keywords
combination
oligonucleotide
treating cancer
antisense oligonucleotides
antineoplastic agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
DE69330137T
Other languages
English (en)
Other versions
DE69330137T2 (de
Inventor
Bruno Calabretta
Thomasz Skorski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thomas Jefferson University
Temple University of Commonwealth System of Higher Education
Original Assignee
Thomas Jefferson University
Temple University of Commonwealth System of Higher Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25510318&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69330137(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Thomas Jefferson University, Temple University of Commonwealth System of Higher Education filed Critical Thomas Jefferson University
Publication of DE69330137D1 publication Critical patent/DE69330137D1/de
Application granted granted Critical
Publication of DE69330137T2 publication Critical patent/DE69330137T2/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69330137T 1992-10-21 1993-08-10 Die kombination von antineoplastischen mitteln und antisense-oligonukleotiden bei der behandlung von krebs Ceased DE69330137T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96567192A 1992-10-21 1992-10-21
PCT/US1993/007541 WO1994008625A1 (en) 1992-10-21 1993-08-10 Combination of antineoplastic agent and antisense oligonucleotides for treatment of cancer

Publications (2)

Publication Number Publication Date
DE69330137D1 true DE69330137D1 (de) 2001-05-17
DE69330137T2 DE69330137T2 (de) 2001-11-15

Family

ID=25510318

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69330137T Ceased DE69330137T2 (de) 1992-10-21 1993-08-10 Die kombination von antineoplastischen mitteln und antisense-oligonukleotiden bei der behandlung von krebs

Country Status (7)

Country Link
EP (1) EP0668782B1 (de)
JP (1) JPH08506087A (de)
AT (1) ATE200427T1 (de)
AU (1) AU5005093A (de)
CA (1) CA2147663A1 (de)
DE (1) DE69330137T2 (de)
WO (1) WO1994008625A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE258596T1 (de) 1993-07-10 2004-02-15 Biognostik Ges Antigens-nukleinsäure enthaltende pharmazeutische zusammensetzung zur verbeugung und/oder behandlung von neuronalen verletzungen, entartungen und zellentot, und zur behandlung von neoplasmen
US5855911A (en) 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
EP0932698A1 (de) * 1996-03-26 1999-08-04 Lynx Therapeutics, Inc. Oligonukleotide zusammenstellungen zur behandlung von menschlichem melanom
EP0941124A4 (de) * 1996-11-21 2004-12-15 Univ Nebraska Antisense-oligonukleotid zusammenstellungen zur gezielten tötung von krebszellen
HUP0100044A3 (en) * 1997-05-05 2003-08-28 Sanofi Aventis Deutschland Modified antisense nucleotides complementary to a section of the human ha-ras gene
US7087580B2 (en) 1998-04-23 2006-08-08 Genesense Technologies, Inc. Neuropilin antisense oligonucleotide sequences and methods of using same to modulate cell growth
US6417169B1 (en) * 1998-04-23 2002-07-09 Genesense Technologies Inc. Insulin-like growth factor II antisense oligonucleotide sequences and methods of using same to inhibit cell growth
US6953783B1 (en) 1998-10-19 2005-10-11 Methylgene, Inc. Modulation of gene expression by combination therapy
AU2004200032B2 (en) * 1998-10-19 2005-05-05 Methylgene, Inc Modulation of gene expression by combination therapy
EP1243290A3 (de) * 1998-10-19 2004-03-17 Methylgene, Inc. Veränderung der Genexpression durch Kombinationstherapie
CA2347003A1 (en) * 1998-10-19 2000-04-27 Methylgene, Inc. Modulation of gene expression by combination therapy
US7795232B1 (en) 2000-08-25 2010-09-14 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055459A (en) * 1986-06-30 1991-10-08 Board Of Regents, The University Of Texas Selective elimination of malignant cells from bone marrow by bis (acyloxy) propylphosphoramidates
WO1991004753A1 (en) * 1989-10-02 1991-04-18 Cetus Corporation Conjugates of antisense oligonucleotides and therapeutic uses thereof

Also Published As

Publication number Publication date
JPH08506087A (ja) 1996-07-02
DE69330137T2 (de) 2001-11-15
AU5005093A (en) 1994-05-09
EP0668782A4 (de) 1998-09-16
EP0668782B1 (de) 2001-04-11
WO1994008625A1 (en) 1994-04-28
CA2147663A1 (en) 1994-04-28
EP0668782A1 (de) 1995-08-30
ATE200427T1 (de) 2001-04-15

Similar Documents

Publication Publication Date Title
DE69330137D1 (de) Die kombination von antineoplastischen mitteln und antisense-oligonukleotiden bei der behandlung von krebs
ATE194383T1 (de) Antisense oligonukleotide gegen die alpha- regulatorische untereinheit der camp-abhängigen protein-kinase zur behandlung von krebs
ZA200304500B (en) Method for inhibiting the expression of a target gene and medicament for treating a tumor disease.
DK1163254T3 (da) TRPM-2 antisense-behandling
HU9403788D0 (en) Self-stabilized oligonucleotides as therapeutic agents
EP0939621A4 (de) Hemmung der bcl-2 protein expression durch liposomale antisense-oligodeoxynukleotide
PT1019040E (pt) Inibicao da actividade de p38-quinase por meio de arilureias
TR199801581T2 (xx) �ekerle de�i�tirilmi� bo�luklu oligon�kleotid'ler.
HU9501963D0 (en) 7-deazapurine modified oligonucleotides
DE69819167D1 (de) Modifizierter, das dorsalgewebe beeinflussender faktor
MXPA03008623A (es) Combinacion farmaceutica para el tratamiento del cancer.
PT1053313E (pt) Oligonucleotidos ''antisense'' optimizados complementares de sequencias de dna metiltransferase
DE69934227D1 (de) Auf beta-arabinose, und dessen analogen, basierte antisense oligonukleotide
DE69328025D1 (de) Dorsalgewebe beeinflussender faktor und zusammensetzungen
BR0008788A (pt) Sequencias anti-sentido antitumor dirigidas contra componentes r1 e r2 de ribonucleotìdeo reductase
FR2790757B1 (fr) Oligonucleotides contenant une sequence antisens stabilises par une structure secondaire et compositions pharmaceutiques les contenant.
WO1999007844A3 (en) Methods and compositions for treatment of restenosis
PT775745E (pt) Aptameros inibidores de catepsina g
DE69841858D1 (de) Medikamente für massive tumore, welche inhibitoren der expression des wilms' tumorgens enthalten
ATE465261T1 (de) Integrin-gekoppelte kinase, ihre hemmstoffe und deren gebrauch für verfahren zur therapeutischen behandlung; gentherapie und bereitstellung von hemmstoffen, die als pseudosubstrate wirken
WO2003030832A3 (en) Antisense therapy using oligonucleotides that target human kinesin genes for treatment of cancer
WO1999025819A3 (de) Antisense oligonukleotide gegen tenascin zur behandlung von vitiligo
AU2180501A (en) Novel DNA polymerase inhibitors, mikanolide and dihydromikanolide
DE10346721A1 (de) Oligonukleotide, diese enthaltende Mittel und deren Verwendung
ATE391777T1 (de) Verwendung von prohibitin-rns in krebsbehandlung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8310 Action for declaration of annulment
8311 Complete invalidation